111 related articles for article (PubMed ID: 22647219)
1. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors.
de Oliveira Lopes R; Romeiro NC; de Lima CK; Louback da Silva L; de Miranda AL; Nascimento PG; Cunha FQ; Barreiro EJ; Lima LM
Eur J Med Chem; 2012 Aug; 54():264-71. PubMed ID: 22647219
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors.
Kulkarni RG; Laufer S; Mangannavar C; Garlapati A
Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566
[TBL] [Abstract][Full Text] [Related]
4. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel anti-cytokine 1,2,4-triazine derivatives.
Khoshneviszadeh M; Ghahremani MH; Foroumadi A; Miri R; Firuzi O; Madadkar-Sobhani A; Edraki N; Parsa M; Shafiee A
Bioorg Med Chem; 2013 Nov; 21(21):6708-17. PubMed ID: 23993677
[TBL] [Abstract][Full Text] [Related]
6. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes.
Lacerda RB; de Lima CK; da Silva LL; Romeiro NC; Miranda AL; Barreiro EJ; Fraga CA
Bioorg Med Chem; 2009 Jan; 17(1):74-84. PubMed ID: 19059783
[TBL] [Abstract][Full Text] [Related]
8. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
Ziegler K; Hauser DR; Unger A; Albrecht W; Laufer SA
ChemMedChem; 2009 Nov; 4(11):1939-48. PubMed ID: 19731280
[TBL] [Abstract][Full Text] [Related]
9. Substituted Benzamides from Anti-inflammatory and p38 Kinase Inhibitors to Antitubercular Activity: Design, Synthesis and Screening.
Kulkarni R; Mitkari U; Achaiah G; Laufer S; Bikshapti DVRN; Chandrashekar VM; Gurav PB; Joshi SJ; Chipade VD
Mini Rev Med Chem; 2018; 18(17):1486-1497. PubMed ID: 28685700
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation.
Zhou HY; Shin EM; Guo LY; Youn UJ; Bae K; Kang SS; Zou LB; Kim YS
Eur J Pharmacol; 2008 May; 586(1-3):340-9. PubMed ID: 18378223
[TBL] [Abstract][Full Text] [Related]
14. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
Kumar S; Votta BJ; Rieman DJ; Badger AM; Gowen M; Lee JC
J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753
[TBL] [Abstract][Full Text] [Related]
15. Involvement of p38 MAP kinase in lipopolysaccharide-induced production of pro- and anti-inflammatory cytokines and prostaglandin E(2) in human choriodecidua.
Shoji T; Yoshida S; Mitsunari M; Miyake N; Tsukihara S; Iwabe T; Harada T; Terakawa N
J Reprod Immunol; 2007 Oct; 75(2):82-90. PubMed ID: 17617469
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors.
Dorn A; Schattel V; Laufer S
Bioorg Med Chem Lett; 2010 May; 20(10):3074-7. PubMed ID: 20418099
[TBL] [Abstract][Full Text] [Related]
17. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
18. Azastilbenes: a cut-off to p38 MAPK inhibitors.
Poon JF; Alao JP; Sunnerhagen P; Dinér P
Org Biomol Chem; 2013 Jul; 11(27):4526-36. PubMed ID: 23719673
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA
J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
